Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
News|Articles|June 3, 2008
Formulary and Managed Healthcare Executive 2008 Media Kit
Formulary and Managed Healthcare Executive 2008 Media Kit
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Pope Leo XIV's lung cancer diagnosis puts a spotlight on low U.S. screening rates
2
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
3
Chronic hand eczema needs more than topical steroids | Fall Clinical Derm 2026
4
U.S. employer-covered healthcare costs: It’s still the prices
5